Position in VKTX
as of Jun 30, 2026
· filed Jul 20, 2026
Position Value
$816,986
+$134,427 QoQ
Shares Held
20,943
-0.2% QoQ
Ownership
0.018%
of shares outstanding
% of Portfolio
0.11%
of 13F equity value
Holder Rank
#179
of 434 holders
Holding Since
Jun 2024
8 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in VKTX Over Time
Shares Held
Position Value (USD)
Derivatives in VKTX
reported options exposure · as of Sep 30, 2024CallValue
$63,310
CallShares
1,000
PutValue
$0
PutShares
0
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Biotechnology
Healthcare · as of Jun 30, 2026Royal Fund Management, LLC holds $892,034 across 2 Biotechnology names. VKTX ranks #1 (91.6% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VKTX |
Viking Therapeutics, Inc.
This page
|
20,943 | $816,986 | |
| 2 | OTLK |
Outlook Therapeutics, Inc.
|
47,200 | $75,048 |
All Filings in VKTX
Export CSV
10 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $816,986 | 20,943 | Shares | Sole | 2026-07-20 | |
| 2026-03-31 | $682,559 | 20,976 | Shares | Sole | 2026-05-19 | |
| 2025-12-31 | $1,518,086 | 43,152 | Shares | Sole | 2026-01-15 | |
| 2025-06-30 | $566,464 | 21,376 | Shares | Sole | 2025-08-13 | |
| 2025-03-31 | $504,517 | 20,891 | Shares | Sole | 2025-05-14 | |
| 2024-12-31 | $1,777,883 | 44,182 | Shares | Sole | 2025-01-16 | |
| 2024-09-30 | $63,310 | 1,000 | Call | Sole | 2024-10-08 | |
| 2024-09-30 | $743,512 | 11,744 | Shares | Sole | 2024-10-08 | |
| 2024-06-30 | $604,314 | 11,400 | Shares | Sole | 2024-07-18 | |
| 2024-06-30 | $68,913 | 1,300 | Call | Sole | 2024-07-18 | |
| No filing history on record for this holder in this stock. | ||||||